SNG.L
Price:
$4.2
Market Cap:
$8.46M
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease; and LOXL2 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) disease. The company has a licensing and collaboration agreement with Pharmaxis Ltd. to develop a LOXL2 inhibitor. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.[Read more]
Industry
Biotechnology
IPO Date
2004-10-26
Stock Exchange
LSE
Ticker
SNG.L
According to Synairgen plc’s latest financial reports and current stock price. The company's current PE Ratio is -1.40. This represents a change of -99.32% compared to the average of -206.41 of the last 4 quarters.
The mean historical PE Ratio of Synairgen plc over the last ten years is 1.72K. The current -1.40 PE Ratio has changed -108.16% with respect to the historical average. Over the past ten years (40 quarters), SNG.L's PE Ratio was at its highest in in the June 2014 quarter at 6.48K. The PE Ratio was at its lowest in in the December 2013 quarter at -10338.97.
Average
1.72K
Median
-3.10
Minimum
-9057.21
Maximum
23.93K
Discovering the peaks and valleys of Synairgen plc PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 877.43%
Maximum Annual PE Ratio = 23.93K
Minimum Annual Increase = -134759.44%
Minimum Annual PE Ratio = -9057.21
Year | PE Ratio | Change |
---|---|---|
2023 | -1.43 | -7.03% |
2022 | -1.54 | -82.02% |
2021 | -8.57 | -47.03% |
2020 | -16.18 | 877.43% |
2019 | -1.65 | -99.96% |
2018 | -3801.08 | -162.17% |
2017 | 6.11K | -134759.44% |
2016 | -4.54 | -99.95% |
2015 | -9057.21 | -137.85% |
2014 | 23.93K | -119414.31% |
The current PE Ratio of Synairgen plc (SNG.L) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
-3.85
5-year avg
-5.87
10-year avg
1.72K
Synairgen plc’s PE Ratio is less than Omega Diagnostics Group PLC (-1.25), greater than Avacta Group Plc (-6.52), less than Novacyt S.A. (-1.03), less than genedrive plc (-0.61), less than Greatland Gold plc (-0.04),
Company | PE Ratio | Market cap |
---|---|---|
-1.25 | $4.94M | |
-6.52 | $188.83M | |
-1.03 | $38.49M | |
-0.61 | $12.85M | |
-0.04 | $642.30M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Synairgen plc using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Synairgen plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Synairgen plc's PE Ratio?
How is the PE Ratio calculated for Synairgen plc (SNG.L)?
What is the highest PE Ratio for Synairgen plc (SNG.L)?
What is the 3-year average PE Ratio for Synairgen plc (SNG.L)?
What is the 5-year average PE Ratio for Synairgen plc (SNG.L)?
How does the current PE Ratio for Synairgen plc (SNG.L) compare to its historical average?